Sinopia Biosciences and Omix Technologies Awarded NIGMS Phase I SBIR to Develop Next-Gen Drug Discovery Platform

The National Institute of General Medical Sciences has awarded Sinopia Biosciences (San Diego, CA) and Omix Technologies (Denver, CO) a Phase I Small Business Innovation Research (SBIR) grant. The grant entitled "Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery” combines Sinopia’s unique and long history of expertise in computational analysis of metabolomics data with Omix’s exceptional ability to generate metabolomics data with unprecedented throughput, accuracy, and precision. This combination will allow for studying drug-like compounds’ effects on cellular systems at a deeper level of biochemical detail than before, with applications in drug discovery, drug repurposing, and drug safety.